Products Categories
CAS No.: | 7632-10-2 |
---|---|
Name: | DL-Methamphetamine |
Article Data: | 44 |
Molecular Structure: | |
Formula: | C10H15N |
Molecular Weight: | 149.236 |
Synonyms: | (+/-)-N-Methylamphetamine;Divk1c_000988; |
Density: | 0.907g/cm3 |
Melting Point: | 134-135 °C |
Boiling Point: | 215.5°Cat760mmHg |
Flash Point: | 86.8°C |
Safety: | Poison by ingestion, intraperitoneal, subcutaneous, and intravenous routes. A powerful central nervous system stimulant. When heated to decomposition it emits toxic fumes of NOx. See also BENZEDRINE. |
PSA: | 12.03000 |
LogP: | 2.22790 |
Chemical Name: DL-Methamphetamine
IUPAC NAME: N-Methyl-1-phenylpropan-2-amine
CAS No.: 7632-10-2
Molecular Formula: C10H15N
Molecular Weight: 149.23 g/mol
Density: 0.907 g/cm3
Flash Point: 86.8 °C
Boiling Point: 215.5 °C at 760 mmHg
Following is the structure of Desoxyn (7632-10-2):
The chemical synonymous of Desoxyn (7632-10-2) are DL-Desoxyephedrine ; Benzeneethanamine, N,a-dimethyl- (9CI) ; dl-Methamphetamin ; Ephedrine, deoxy- ; N,a-Dimethylbenzeneethanamine ; N,a-Dimethylphenethylamine
In November 1943, Abbott Laboratories submitted a New Drug Application (NDA) to the Drug Division at the U.S. Food and Drug Administration (FDA) for Desoxyn. Abbott requested approval for narcolepsy, mild depression, postencephalitic parkinsonism, chronic alcoholism, cerebral arteriosclerosis, and hay fever. The NDA included review articles from academic journals, case histories from physicians, and a 3-page testimonial from a patient with narcolepsy. All these requests were accepted, and the drug was approved in December, 1944. All of these indication approvals were eventually removed. The only two approved marketing indications remaining for methamphetamine are for ADHD and the short-term management of exogenous obesity, although the drug is clinically established as effective in the treatment of narcolepsy.A sustained-release formulation of methamphetamine in the form of a plastic-matrix tablet, named the Desoxyn Gradumet, was introduced after the standard Desoxyn formulation was introduced. Abbott discontinued production of the Desoxyn Gradumet in the Fall of 1999, citing "manufacturing difficulties" as the reason for its discontinuation. The 5 milligram immediate release tablet is the only formulation presently available.In a joint sale for US$40 million, Abbott sold their rights to Desoxyn and Tranxene to Ovation Pharmaceuticals. Able Labs produced the first generic formulation of methamphetamine hydrochloride in 2004, until the company went out of business the following year.
Desoxyn (7632-10-2) is considered to have significant abuse potential.It is considered to not have any greater risk of misuse and addiction than its close relative amphetamine, although methamphetamine causes a higher degree of euphoria, a lesser degree of adverse physical reactions, and a longer lasting duration of effects than amphetamine.
1. | orl-rat LDLo:70 mg/kg | AEPPAE Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 195 (1940),647. | ||
2. | ipr-rat LDLo:32 mg/kg | AEPPAE Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 195 (1940),647. | ||
3. | scu-rat LD50:30 mg/kg | AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. 159 (1966),442. | ||
4. | orl-mus LD50:34 mg/kg | JPETAB Journal of Pharmacology and Experimental Therapeutics. 131 (1961),115. | ||
5. | ipr-mus LD50:15 mg/kg | CPBTAL Chemical and Pharmaceutical Bulletin. 22 (1974),1459. | ||
6. | scu-mus LD50:10 mg/kg | AEPPAE Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie. 241 (1961),182. | ||
7. | ivn-mus LD50:10 mg/kg | 27ZIAQ Drug Dosages in Laboratory Animals-A Handbook C.D. Barnes andL.G. Eltherington,Berkeley, CA.: Univ. of California Press,1965 | ||
8. | scu-cat LDLo:50 mg/kg | 27ZIAQ Drug Dosages in Laboratory Animals-A Handbook C.D. Barnes andL.G. Eltherington,Berkeley, CA.: Univ. of California Press,1973,158. |
Poison by ingestion, intraperitoneal, subcutaneous, and intravenous routes. A powerful central nervous system stimulant. When heated to decomposition it emits toxic fumes of NOx. See also BENZEDRINE.
Desoxyn (7632-10-2) is a psychostimulant drug intended for medical usage in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD),narcolepsy and for the short-term treatment of exogenous obesity.It is currently a Schedule II substance of the Controlled Substances Act in the United States. Drugs that are listed as Schedule II substances, such as methamphetamine, are drugs that are recognized to have a high risk for misuse, physical addiction, and/or psychological addiction, but they still have clinically accepted medical usage, Schedule II drugs are the most restricted of drugs with accepted medicinal use.and it is a potent central nervous system stimulant that acts as a substrate at the norepinephrine, dopamine (DA) and serotonin (5-HT) neurotransmitters, triggering an influx of these neurotransmitters from the cytosol into the trans-synaptic space via a process of 'reverse transport' by the monoamine reuptake transporter proteins (in which methamphetamine molecules are exchanged for endogenous monoamine substrate molecules). The compound also inhibits the reuptake of the transmitters into the pre-synaptic neuron by competing for uptake as substrates for the transporter, causing them to remain in the synaptic cleft longer. The resulting increased levels of dopamine and norepinephrine in these synapses affect neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and responses associated with alertness or alarm conditions. While amphetamine and methamphetamine have similar effects on dopamine and noradrenaline release, methamphetamine is a far more effective agonist of serotonin.